Business
Ionis and AstraZeneca to develop and commercialize eplontersen
- Collaboration expected to enable faster and deeper market penetration into growing global TTR amyloidosis market - The companies will jointly develop and
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"text","content":"- Collaboration expected to enable faster and deeper market penetration into growing global TTR amyloidosis market\n - The companies will jointly develop and commercialize eplontersen in the U.S., AstraZeneca has exclusive rights to commercialize in rest of the world\n - Bolsters Ionis' commercial organization as it prepares for multiple product launches\n - Ionis to hold webcast Dec. 7, 2021, at 10 a.m. Eastern Time\n\n\nCARLSBAD, Calif., Dec. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has entered into a strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis (ATTR). \n\n \n \n \n \n \n \n\n \nEplontersen, formerly known as IONIS-TTR-LRx, is designed to reduce the production of transthyretin, or TTR protein, to treat ATTR, a systemic, progressive and fatal disease. It uses Ionis' advanced LIgand-Conjugated Antisense (LICA) technology.\nThe companies will develop a global strategy for developing, manufacturing and commercializing eplontersen. A breakdown of responsibilities of the collaboration includes, but is not limited to:\nIonis will continue to lead the conduct of the global Phase 3 clinical trials in patients with hereditary ATTR amyloidosis (hATTR) with polyneuropathy (NEURO-TTRansform) and cardiomyopathy (CARDIO-TTRansform). Ionis will manufacture and supply eplontersen for the ongoing clinical trials and process qualifications. AstraZeneca will be responsible for commercial supply, with transition timing to be agreed by both companies. Ionis and AstraZeneca will have shared responsibility for medical affairs and commercial activities in the U.S. AstraZeneca will have an exclusive license for eplontersen outside the U.S. except certain countries in Latin America.\"We believe that bringing together Ionis' industry-leading experience in RNA-targeted therapeutics and deep knowledge of the TTR amyloidosis market with AstraZeneca's global scale and leadership in cardiovascular drug development and commercialization will enable faster and deeper market penetration for the benefit of patients,\" said Brett P. Monia, Ph.D., chief executive officer of Ionis. \"In addition to being the best strategy to maximize patient and sh...